Osteoporosis Primer for the Vertebroplasty Practitioner: Expanding the Focus Beyond Needles and Cement

References

1. ↵
   Hooven F, Gehlbach SH, Pekow P, et al. Follow-up treatment for osteoporosis after fracture. Osteoporos Int 2005;16:296–301

   CrossRefPubMedWeb of Science
2. ↵
   Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001–05

   Abstract/FREE Full Text
3. ↵
   Ross PD, Davis JW, Epstein RS, et al. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919–23

   CrossRefPubMedWeb of Science
4. ↵
   Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320–03

   CrossRefPubMedWeb of Science
5. ↵
   Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000;15:1384–92

   CrossRefPubMedWeb of Science
6. ↵
   Ismail AA, Cockerill W, Cooper C, et al. Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study. Osteoporos Int 2001;12:85–90

   CrossRefPubMedWeb of Science
7. ↵
   Compston JE, Vedi S, Kaptoge S, et al. Bone remodeling rate and remodeling balance are not co-regulated in adulthood: implications for the use of activation frequency as an index of remodeling rate. J Bone Miner Res 2007;22:1031–36

   CrossRefPubMed
8. ↵
   Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508–14

   Abstract/FREE Full Text
9. ↵
   Riggs BL, Melton LJ 3rd, O'Fallon WM. Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996;18 (suppl 3):197S–201S

   CrossRefPubMed
10. ↵
    Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570–78

    CrossRefPubMedWeb of Science
11. ↵
    Cooper C, Melton III L. Epidemiology of osteoporosis. Trends Endocrinol Metab 1992;3:224–29

    CrossRefPubMedWeb of Science
12. ↵
    Ivaska KK, Gerdhem P, Akesson K, et al. Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 2007;22:1155–64

    CrossRefPubMedWeb of Science
13. ↵
    Nevitt MC, Cummings SR, Stone KL, et al. Risk factors for a first-incident radiographic vertebral fracture in women > or = 65 years of age: the study of osteoporotic fractures. J Bone Miner Res 2005;20:131–40. Epub 2004 Oct 11

    CrossRefPubMedWeb of Science
14. ↵
    Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87:4431–37

    CrossRefPubMedWeb of Science
15. ↵
    Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 2005;16:155–62

    CrossRefPubMedWeb of Science
16. ↵
    Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669–83

    CrossRefPubMedWeb of Science
17. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560–69

    CrossRefPubMedWeb of Science
18. ↵
    Shea B, Wells G, Cranney A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev 2002;23:552–59

    CrossRefPubMedWeb of Science
19. ↵
    Sebring NG, Denkinger BI, Menzie CM, et al. Validation of three food frequency questionnaires to assess dietary calcium intake in adults. J Am Diet Assoc 2007;107:752–59

    CrossRefPubMedWeb of Science
20. ↵
    Jackson C, Gaugris S, Sen SS, et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 2007;100:185–92

    Abstract/FREE Full Text
21. ↵
    Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metabol 2008;93:677–81. Epub 2007 Dec 18

    CrossRefPubMedWeb of Science
22. ↵
    Michaelsson K, Olofsson H, Jensevik K, et al. Leisure physical activity and the risk of fracture in men. PLoS Mede 2007;4:e199

    CrossRef
23. ↵
    Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. JAMA 2002;288:2300–06

    CrossRefPubMedWeb of Science
24. ↵
    Liu-Ambrose T, Khan KM, Eng JJ, et al. Resistance and agility training reduce fall risk in women aged 75 to 85 with low bone mass: a 6-month randomized, controlled trial. J Am Geriatr Soc 2004;52:657–65

    CrossRefPubMedWeb of Science
25. ↵
    Trout AT, Kallmes DF, Kaufmann TJ. New fractures after vertebroplasty: adjacent fractures occur significantly sooner. AJNR Am J Neuroradiol 2006;27:217–23

    Abstract/FREE Full Text
26. ↵
    Huntoon EA, Schmidt CK, Sinaki M. Significantly fewer refractures after vertebroplasty in patients who engage in back-extensor-strengthening exercises. Mayo Clin Proc 2008;83:54–7

    CrossRefPubMed
27. ↵
    Maclean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197–213. Epub 2007 Dec 17

    CrossRefPubMedWeb of Science
28. ↵
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41

    CrossRefPubMedWeb of Science
29. ↵
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22

    CrossRefPubMedWeb of Science
30. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–49. Epub 2004 Mar 29

    CrossRefPubMedWeb of Science
31. ↵
    Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077–82

    CrossRefPubMedWeb of Science
32. ↵
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001;344:333–40

    CrossRefPubMedWeb of Science
33. ↵
    Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548–58

    CrossRefPubMedWeb of Science
34. ↵
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12

    CrossRefPubMedWeb of Science
35. ↵
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial—Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–45

    CrossRefPubMedWeb of Science
36. ↵
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–47

    CrossRefPubMedWeb of Science
37. ↵
    Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727–41. Epub 2006 Jun 5

    CrossRefPubMedWeb of Science
38. ↵
    Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study—PROOF Study Group. Am J Med 2000;109:267–76

    CrossRefPubMedWeb of Science
39. ↵
    Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556–61

    Abstract/FREE Full Text
40. ↵
    Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 2002;13:858–67

    CrossRefPubMedWeb of Science
41. ↵
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–41

    CrossRefPubMedWeb of Science
42. ↵
    Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216–26

    CrossRefPubMedWeb of Science
43. ↵
    Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:4528–35

    CrossRefPubMedWeb of Science
44. ↵
    Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006;91:2882–87

    CrossRefPubMedWeb of Science
45. ↵
    Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129–34

    CrossRefPubMedWeb of Science
46. ↵
    Evio S, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004;89:626–31

    CrossRefPubMedWeb of Science
47. ↵
    Johnell O, Scheele WH, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002;87:985–92

    CrossRefPubMedWeb of Science